Pneumococcal vaccination in children with acute lymphocytic leukemia.
Sixty-three children with ALL in CCR and treated according to a standard therapy protocol were immunized with the 14-valent pneumococcal vaccine. Forty-six children were vaccinated 1, 3, or 6 months following initial induction remission; 15 were vaccinated 4-6 weeks following successful completion of 30 months of antileukemia therapy; and two were vaccinated at the time of diagnosis. Response to the vaccine was suboptimal and by the 6-month follow-up there were only two serotypes for which more than half the patients tested had greater than or equal to 300 ng antibodies N/ml.
D000293:Adolescent; D000907:Antibodies, Bacterial / Q000032:analysis; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D001428:Bacterial Vaccines; D002648:Child; D002675:Child, Preschool; D006801:Humans; D007945:Leukemia, Lymphoid / Q000188:drug therapy / Q000276:immunology*; D011008:Pneumococcal Infections / Q000276:immunology / Q000517:prevention & control*; D011446:Prospective Studies; D013296:Streptococcus pneumoniae / Q000276:immunology*; D013997:Time Factors; D014611:Vaccination
D000907:Antibodies, Bacterial; D001428:Bacterial Vaccines